August 28th, 2013
Platelet Reactivity Testing: Do You or Don’t You?
Richard A. Lange, MD, MBA and L. David Hillis, MD
In light of recent findings from the ADEPT DES study, Richard Lange and David Hillis want to know: Do you test PCI patients for platelet reactivity, and if so, why? React to reactivity in our latest poll.
January 18th, 2012
Cangrelor and Alaska’s “Bridge to Nowhere”
Richard A. Lange, MD, MBA and L. David Hillis, MD
The Gravina Island Bridge (also known as The Bridge to Nowhere) was a proposed bridge to replace the ferry that currently connects Ketchikan, Alaska (population, 14,000) to the Ketchikan International Airport on Gravina Island (population, 50) at a projected cost of $398 million. The bridge was to have been nearly as long as the Golden Gate […]
November 16th, 2010
GRAVITAS: No Benefit for Clopidogrel Dosing Based on Platelet Function Test
Larry Husten, PHD
The GRAVITAS (Gauging Responsiveness With A VerifyNow Assay ─ Impact on Thrombosis and Safety) trial enrolled 2214 patients with high residual platelet reactivity, as assessed by the VerifyNow P2Y12 Test measured 12 to 24 hours after the procedure. (The manufacturer of the test, Accumetrics, sponsored the trial.) Patients in the trial were randomized to either high-dose clopidogrel […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?